ARTICLE | Company News
Rheos spins immunometabolism platform into deal with Roche
December 19, 2019 1:07 PM UTC
Updated on Dec 20, 2019 at 12:44 AM UTC
Roche has teamed up with Rheos Medicine in a deal that lends validation to the emerging theory that immune cell reprogramming has big therapeutic potential.
Rheos Medicine Inc. will receive $42.5 million up front from Roche (SIX:ROG; OTCQX:RHHBY) plus up to about $90 million in research and preclinical development milestones and option fees. Rheos is eligible for $660 million in development, regulatory and sales milestones, and tiered royalties...